Midostaurin (PKC412)

Catalog No.S8064 Synonyms: CGP 41251

Midostaurin (PKC412) Chemical Structure

Molecular Weight(MW): 570.64

Midostaurin (pkc412) is a multi-targeted kinase inhibitor, including PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC50 ranging from 80-500 nM.

Size Price Stock Quantity  
USD 110 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Purity & Quality Control

Choose Selective PKC Inhibitors

Biological Activity

Description Midostaurin (pkc412) is a multi-targeted kinase inhibitor, including PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC50 ranging from 80-500 nM.
Targets
PKCα [1]
(Cell-free assay)
PKCγ [1]
(Cell-free assay)
PKCβ1 [1]
(Cell-free assay)
PKCβ2 [1]
(Cell-free assay)
PPK [1]
(Cell-free assay)
22 nM 24 nM 30 nM 31 nM 38 nM
In vitro

Midostaurin(pkc412) is a broad spectrum protein kinase inhibitor. Midostaurin(pkc412) interacts strongly with ATP binding sites of the conventional PKC-α, -β and -γ, PDGFRβ, VEGF-R2, VEGF-R1 and the cyclin-dependant kinase 1-cyclin B complex. Midostaurin(pkc412) inhibits the growth of various human and animal cell lines in vitro at similar submicromolar concentrations. Midostaurin(pkc412) also effectively inhibits the in vitro proliferation of glioblastoma and induced the accumulation of cells in G2/M and formation of giant nuclei with extensive fragmentation and apoptotic bodies. Midostaurin(pkc412) is able to reverse the p-glycoprotein-mediated multidrug resistance of tumor cells in vitro. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human MV4-11 cells NHq4ZVREgXSxdH;4bYNqfHliYYPzZZk> NEHweGM4OiCq Mk[5R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUXY1NTFzIHPlcIx{KGGodHXyJFczKGi{czDifUBk\WyuIITpeIVzNWKudXWgZZN{[XluIFnDOVA:OTJibl2= MlTKNVk3PTR2MEi=
RS4-11 cells M3;rSmZ2dmO2aX;uJIF{e2G7 NV75eGw6OiCq NH7VXFNKdmirYnn0bY9vKG:oIF\MWFMhUVSGIH31eIFvfCCjdYTvdIhwe3Cqb4L5cIF1cW:wIHnuJIh2dWGwIGLTOE0yOSClZXzsd{Bi\nSncjCyJIhzeyCkeTDlcIVkfHKxY3jlcYltfW2rbnXzZ4Vv[2ViYYPzZZktKEmFNUC9NVMhdk1? NHrrTZYyQTZ3NESwPC=>
CGTH-W-1 cell NV\IS4Q5T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4S5SWlvcGmkaYTpc44hd2ZiaIXtZY4hS0eWSD3XMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01Oi54NTFOwG0> M3;pXHNCVkeHUh?=
SW982 cell M2\Od2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYHkUJFOUW6qaXLpeIlwdiCxZjDoeY1idiCVV{m4NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQ2NjV6IN88US=> NEXsN4xUSU6JRWK=
human EoL-1-cell cell MUjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NWm3NJFJUW6qaXLpeIlwdiCxZjDoeY1idiCHb1ytNU1k\WyuIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NUKuNFghdk1? NVHoOY9ZW0GQR1XS
MOLM-13 cells NHnGcWJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NY[4OYhVPzJiaB?= MVvJcohq[mm2aX;uJI9nKE[OVEOgTXRFKGindHXyc5p6\2:3czDteZRidnRiaX6gbJVu[W5iTV;MUU0yOyClZXzsd{Bie3Onc4Pl[EBieyClZXzsJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IEeyJIhzeyCkeTDNWHMh[XO|YYmsJGdKPTB;MD6wOVUh|ryP M{LSXlI3ODhzMEKz
KASUMI-1 cell MUjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M4DQOmlvcGmkaYTpc44hd2ZiaIXtZY4hU0GVVV3JMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjB4MEG2JO69VQ>? MnHSV2FPT0WU
NCI-H1755 cell NIi0OIJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXTJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMUe1OUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvODZ{N{Og{txO MlWwV2FPT0WU
human MES-SA cell M1rIR2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NH7IeW9KdmirYnn0bY9vKG:oIHj1cYFvKE2HUz3TRUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvODd3NESg{txO MULTRW5ITVJ?
human HCC1395 cell NEizbodIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXHJcohq[mm2aX;uJI9nKGi3bXHuJGhESzF|OUWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlA5PDJ6IN88US=> M1THc3NCVkeHUh?=
human D-336MG cell M{HNTmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVrJcohq[mm2aX;uJI9nKGi3bXHuJGQuOzN4TVegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlA5PzV2IN88US=> M1qwbHNCVkeHUh?=
CHP-212 cell MY\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M4fnRWlvcGmkaYTpc44hd2ZiaIXtZY4hS0iSLUKxNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvODh5N{Og{txO NXv0NVh[W0GQR1XS
human KM12 cell MkXWS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGPZUm5KdmirYnn0bY9vKG:oIHj1cYFvKEuPMUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlA6Ojd3IN88US=> M3WzOHNCVkeHUh?=
A204 cell MVTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVjJcohq[mm2aX;uJI9nKGi3bXHuJGEzODRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkGwNFUzKM7:TR?= MWrTRW5ITVJ?
CAL-51 cell Ml7mS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MnzRTY5pcWKrdHnvckBw\iCqdX3hckBESUxvNUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlExPzB7IN88US=> MWXTRW5ITVJ?
human A431 cell MXPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHLBUG9KdmirYnn0bY9vKG:oIHj1cYFvKEF2M{GgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlEyOjF4IN88US=> NX7FPI9vW0GQR1XS
NCI-H650 cell NIfBeGxIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NHXDbpVKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IOlUxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5zMUewPEDPxE1? NWT0dWJIW0GQR1XS
A427 cell M1zUcWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGO2TIFKdmirYnn0bY9vKG:oIHj1cYFvKEF2MkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlEyQTF6IN88US=> NH\iU4xUSU6JRWK=
human 769-P cell NXzKOIdIT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVHLc5RuUW6qaXLpeIlwdiCxZjDoeY1idiB5NkmtVEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTJyOEKg{txO M{\uZXNCVkeHUh?=
SW1710 cell M4X4c2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVrJcohq[mm2aX;uJI9nKGi3bXHuJHNYOTdzMDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVM{OTZizszN MUTTRW5ITVJ?
human H4 cell NWD3PJc3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3i5Z2lvcGmkaYTpc44hd2ZiaIXtZY4hUDRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkGzPVY{KM7:TR?= NInC[FRUSU6JRWK=
HT-1080 cell MV7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVvJcohq[mm2aX;uJI9nKGi3bXHuJGhVNTFyOECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlE2QTh{IN88US=> MkDJV2FPT0WU
human PANC-03-27 cell MUXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M2[ySGlvcGmkaYTpc44hd2ZiaIXtZY4hWEGQQz2wN{0zPyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMU[wNkDPxE1? M3\XNHNCVkeHUh?=
A375 cells M2K4cGN6fG:2b4jpZ4l1gSCjc4PhfS=> MkfvO|IhcA>? Mk\sWI95cWOrdImgZYdicW6|dDDoeY1idiCDM{e1JINmdGy|IHHmeIVzKDd{IHjyd{BjgSClZXzsJJRqfGW{LXLseYUh[XO|YYmsJGlEPTB;MD6xPEDPxE1? Mn;INVk3PTR2MEi=
human HOP-62 cell NYTxOXVkTnWwY4Tpc44h[XO|YYm= NIn2TGpKdmirYnn0bY9vKG:oIHj1cYFvKEiRUD22NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOThyN{Og{txO NGTFS|VUSU6JRWK=
human U031 cell NWHON5U4T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MXrJcohq[mm2aX;uJI9nKGi3bXHuJHUxOzFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkG5Olk5KM7:TR?= MUHTRW5ITVJ?
mouse BAF3 cells NVLZfldvWHKxbHnm[ZJifGmxbjDhd5NigQ>? NUDhUZhWSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBud3W|ZTDCRWY{KGOnbHzzJJRz[W6|Zn;ycYVlKHerdHigXm5HOTl6LV\HSnIyKGOxboP0dpVkfCxiSVO1NF0xNjJizszN M3y1VlIyQTN4NUSy
human G-402 cell NEPFWJRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3LaPWlvcGmkaYTpc44hd2ZiaIXtZY4hTy12MEKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlIxOjV|IN88US=> M4TXeXNCVkeHUh?=
human G-361 cell MWDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXLJcohq[mm2aX;uJI9nKGi3bXHuJGcuOzZzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6yNFg2OyEQvF2= NGPQWIJUSU6JRWK=
NCI-H810 cell NWXBcIM1T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MlrBTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEixNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjFyMkeg{txO MY\TRW5ITVJ?
NCI-H2030 cell MlT2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXfJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMkCzNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjNyME[g{txO M{PJTXNCVkeHUh?=
human HCT-116 cell MnrqS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Ml;1TY5pcWKrdHnvckBw\iCqdX3hckBJS1RvMUG2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4zOzV4ODFOwG0> Mm\pV2FPT0WU
human SNU-423 cell NXTudYI5T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mm\KTY5pcWKrdHnvckBw\iCqdX3hckBUVlVvNEKzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4zOzZ3NzFOwG0> M3v4XHNCVkeHUh?=
human SCC-4 cell MlftS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MUPJcohq[mm2aX;uJI9nKGi3bXHuJHNESy12IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6yN|k3PyEQvF2= M{PIZXNCVkeHUh?=
human SW48 cell MWLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Ml\aTY5pcWKrdHnvckBw\iCqdX3hckBUXzR6IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6yOlY5KM7:TR?= NYPDWWhKW0GQR1XS
human SF295 cell NE\uWVVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3\ENGlvcGmkaYTpc44hd2ZiaIXtZY4hW0Z{OUWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlI4OjV5IN88US=> MoTYV2FPT0WU
MDA-MB-231 cell MkTLS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1jHOGlvcGmkaYTpc44hd2ZiaIXtZY4hVUSDLV3CMVI{OSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMkixNFEh|ryP MlTNV2FPT0WU
A172 cell M4D1cWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MUDJcohq[mm2aX;uJI9nKGi3bXHuJGEyPzJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkK5NVUh|ryP MXzTRW5ITVJ?
human BCPAP cell MmTnS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGXRTopKdmirYnn0bY9vKG:oIHj1cYFvKEKFUFHQJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4zQTh5OTFOwG0> NHvv[21USU6JRWK=
human COLO-792 cell M3PKRmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MkHVTY5pcWKrdHnvckBw\iCqdX3hckBEV0yRLUe5NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjl7N{Kg{txO M4C5SHNCVkeHUh?=
human DU-145 cell MXPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MYjJcohq[mm2aX;uJI9nKGi3bXHuJGRWNTF2NTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuN|E5QDlizszN MnTOV2FPT0WU
NCI-H2122 cell MYrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NW\M[WVwUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFIyOjJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkOyNlg2KM7:TR?= MlrYV2FPT0WU
human SK-UT-1 cell NHz1doVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MV7Jcohq[mm2aX;uJI9nKGi3bXHuJHNMNVWWLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlMzQTV{IN88US=> M1HP[nNCVkeHUh?=
LXF-289 cell NV7uU3JKT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVvJcohq[mm2aX;uJI9nKGi3bXHuJGxZTi1{OEmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlMzQTZ3IN88US=> MWHTRW5ITVJ?
human NCI-H1792 cell MnHaS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NUX0V4JxUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFE4QTJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkOzNFk3KM7:TR?= MWDTRW5ITVJ?
MCF7 cell Mk\aS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXnaRpFVUW6qaXLpeIlwdiCxZjDoeY1idiCPQ1[3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{OzJ5NDFOwG0> NWfGeXNOW0GQR1XS
HCT-15 cell M{TLXWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NWK0R5BSUW6qaXLpeIlwdiCxZjDoeY1idiCKQ2StNVUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjN|NEOyJO69VQ>? MkOyV2FPT0WU
human NCI-H358 cell MVnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MX;Jcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KM{W4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{OzV3MTFOwG0> MX\TRW5ITVJ?
human HLE cell NWDoZpJYT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFr2b3FKdmirYnn0bY9vKG:oIHj1cYFvKEiORTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuN|M4PTJizszN NVX2S3B7W0GQR1XS
human SW1088 cell MmrPS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVzJcohq[mm2aX;uJI9nKGi3bXHuJHNYOTB6ODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuN|M4QTdizszN M{HLNHNCVkeHUh?=
human K5 cell M4TQZ2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mm\MTY5pcWKrdHnvckBw\iCqdX3hckBMPSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwM{[xOFkh|ryP M2XOWnNCVkeHUh?=
human SR cell M1nPbmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MnHYTY5pcWKrdHnvckBw\iCqdX3hckBUWiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwM{[1O|Eh|ryP MnnBV2FPT0WU
human Calu-3 cell M1iwR2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M4DFemlvcGmkaYTpc44hd2ZiaIXtZY4hS2GudT2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{Pjh{NTFOwG0> Mk\xV2FPT0WU
human SK-MEL-30 cell M37jbGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NUf2cnNPUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3NSWwuOzBiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkO5PVE{KM7:TR?= NYrUb49MW0GQR1XS
human SW780 cell MorBS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4LTOmlvcGmkaYTpc44hd2ZiaIXtZY4hW1d5OECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlQyOTR{IN88US=> NIfuVHpUSU6JRWK=
NCI-H1563 cell MXHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGDKbZNKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVU3OyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwNEG0PFQh|ryP NFT1Um9USU6JRWK=
human MKN45 cell MlmxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYjJcohq[mm2aX;uJI9nKGi3bXHuJG1MVjR3IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD60NVk{OSEQvF2= NU\EVVlWW0GQR1XS
MDA-MB-157 cell MlLWS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWTJcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj2xOVch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjR{MEG1JO69VQ>? NXXNOIZ2W0GQR1XS
human NCI-H522 cell M{TpVmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHXJUJpKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IOVIzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC52MkOg{txO Mly5V2FPT0WU
human A2780 cell MoHqS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYTJcohq[mm2aX;uJI9nKGi3bXHuJGEzPzhyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD60O|UxOyEQvF2= MWPTRW5ITVJ?
human A498 cell NVrkUJRPT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYTJcohq[mm2aX;uJI9nKGi3bXHuJGE1QThiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkS3Olk{KM7:TR?= NHT3[pNUSU6JRWK=
human BxPC-3 cell NI\C[VFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVu5dJhuUW6qaXLpeIlwdiCxZjDoeY1idiCEeGDDMVMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjR7M{[2JO69VQ>? Ml24V2FPT0WU
human A2058 cell MmPUS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NEG3[2hKdmirYnn0bY9vKG:oIHj1cYFvKEF{MEW4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE42Ojh2NDFOwG0> M4\OSHNCVkeHUh?=
human PC-14 cell MV3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MX7Jcohq[mm2aX;uJI9nKGi3bXHuJHBENTF2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD61N|g2PSEQvF2= MXnTRW5ITVJ?
human KG-1 cell NH7iVFZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWnJcohq[mm2aX;uJI9nKGi3bXHuJGtINTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkW1OFE6KM7:TR?= MY\TRW5ITVJ?
human A375 cell Ml7JS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NEDCfnJKdmirYnn0bY9vKG:oIHj1cYFvKEF|N{WgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlU3OTB|IN88US=> Ml;4V2FPT0WU
human SW1783 cell MUHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M2rOdmlvcGmkaYTpc44hd2ZiaIXtZY4hW1dzN{izJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE44OzN5IN88US=> MkTIV2FPT0WU
human MKN1 cell NXLJT3o5T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NEX4fHhKdmirYnn0bY9vKG:oIHj1cYFvKE2NTkGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlg5PDF{IN88US=> MorpV2FPT0WU
NCI-H1650 cell MnTES5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWO3VG54UW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFE3PTBiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLki4PVE364DCzszN MnPuV2FPT0WU
human HT-1376 cell MWLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NUH1WpcyUW6qaXLpeIlwdiCxZjDoeY1idiCKVD2xN|c3KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC57MkmxPEDPxE1? MlnZV2FPT0WU
SW872 cell MnmzS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGjzU45KdmirYnn0bY9vKG:oIHj1cYFvKFOZOEeyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE46PDR3OTFOwG0> MW\TRW5ITVJ?
human RT-112 cell NX;uRWo{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYDJcohq[mm2aX;uJI9nKGi3bXHuJHJVNTFzMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuPVc1QDNizszN M4\5ZnNCVkeHUh?=
human HT-29 cell NWr1enMyT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MWXJcohq[mm2aX;uJI9nKGi3bXHuJGhVNTJ7IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD65O|k6PiEQvF2= NYeyS4JmW0GQR1XS
human U-266 cell MXvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHniOVJKdmirYnn0bY9vKG:oIHj1cYFvKFVvMk[2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE46QDNyMjFOwG0> NXTvNIVyW0GQR1XS
human HEL cell MVzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYXKTW9ZUW6qaXLpeIlwdiCxZjDoeY1idiCKRVygZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlk5PTF5IN88US=> MV3TRW5ITVJ?
human KU812 cell MWTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MUfJcohq[mm2aX;uJI9nKGi3bXHuJGtWQDF{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT6xNVE3PCEQvF2= NFj5TlVUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo Midostaurin(pkc412) may suppress tumor growth by inhibiting tumor angiogenesis (via its effects on the VEGF receptor tyrosine kinases) in addition to directly inhibiting tumor cell proliferation (via its effects on PKCs). This anti-angiogenic action may contribute to the antimetastatic and broad antitumor activity displayed by midostaurin(pkc412), as well as the synergy with cytotoxic agents, including doxorubicin, cyclophosphamide, cisplatin and gemcitabine. When given orally, the maximally tolerated dose for midostaurin(pkc412) is >300 mg/kg. [1]

Protocol

Cell Research:[2]
+ Expand
  • Cell lines: A549, NCI-H520
  • Concentrations: ~1.0 μM
  • Incubation Time: 24-72 h
  • Method: Each well is added with 5 mM WST-1 and 0.2 mM 1-methoxy PMS and the absorbance at 450 nm is measured by a Microplate Reader.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: Colo 205 colorectal tumors xenograft
  • Formulation: sterile water
  • Dosages: 50 mg/kg, 200 mg/kg, once daily
  • Administration: p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (175.24 mM)
Ethanol 20 mg/mL warmed (35.04 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+45% PEG 300+ddH2O
For best results, use promptly after mixing.
4mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 570.64
Formula

C35H30N4O4

CAS No. 120685-11-2
Storage powder
in solvent
Synonyms CGP 41251

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03207334 Withdrawn Acute Myeloid Leukemia University of Florida|Novartis Pharmaceuticals November 2018 Phase 2
NCT03591510 Not yet recruiting FLT3-mutated Acute Myeloid Leukemia Novartis Pharmaceuticals|Novartis October 12 2018 Phase 2
NCT03258931 Recruiting Newly Diagnosed FLT3 Mutated AML Arog Pharmaceuticals Inc. August 15 2018 Phase 3
NCT03686345 Active not recruiting Core Binding Factor Acute Myeloid Leukemia (CBF-AML) Niguarda Hospital July 1 2018 Phase 2
NCT03512197 Recruiting Acute Myeloid Leukemia (AML) Novartis Pharmaceuticals|Novartis July 20 2018 Phase 3
NCT03280030 Recruiting Acute Myeloid Leukemia Novartis Pharmaceuticals|Novartis April 6 2018 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PKC Signaling Pathway Map

Related PKC Products0

Tags: buy Midostaurin (PKC412) | Midostaurin (PKC412) supplier | purchase Midostaurin (PKC412) | Midostaurin (PKC412) cost | Midostaurin (PKC412) manufacturer | order Midostaurin (PKC412) | Midostaurin (PKC412) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID